VECT NASDAQ
VectivBio Holding AG
1W: -0.4%
1M: +1.5%
3M: +93.7%
1Y: +182.7%
$16.87
Last traded 2023-07-07 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
#341
of 1064
Biotechnology
Technical Signal Map
5 Bullish
3 Neutral
5 Bearish
VECT
$1.1B
VectivBio Holding AG
N/A
0
6160.HK
$282B
BeOne Medicines AG
BULLISH
+75
LONN.SW
$49B
Lonza Group AG
BULLISH
+66
CRSP
$5.3B
CRISPR Therapeutics AG
BULLISH
+41
688235.SS
$276B
BeOne Medicines Ltd. Class A
BULLISH
+36
BSLN.SW
$940M
Basilea Pharmaceutica AG
BULLISH
+31
ACIU
$280M
AC Immune S.A.
NEUTRAL
+9
BANB.SW
$6.8B
Bachem Holding AG
NEUTRAL
-1
PHVS
$2.2B
Pharvaris N.V.
BEARISH
-84
IDIA.SW
$1.4B
Idorsia Ltd
BEARISH
-84
MLTX
$960M
MoonLake Immunotherapeutics
BEARISH
-91
0RQE.IL
$1.2B
Idorsia Ltd.
BEARISH
-100
OCS
$500M
Oculis Holding AG
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| VECT VectivBio Holding AG | $1.1B | -8.0 | -84.7 | -5479.4 | -4212.8 | — | 2 | N/A | 182.7 |
| 6160.HK BeOne Medicines AG | $282B | 61.2 | 14.6 | 57.1 | 13.9 | 34.2 | 8 | BULLISH | 12.8 |
| LONN.SW Lonza Group AG | $49B | -373.2 | 7.1 | 17.8 | 17.5 | 3.1 | 6 | BULLISH | -0.6 |
| CRSP CRISPR Therapeutics AG | $5.3B | -12.0 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BULLISH | -21.3 |
| 688235.SS BeOne Medicines Ltd. Class A | $276B | 26.3 | 14.7 | 57.4 | 13.9 | 31.9 | 8 | BULLISH | 17.7 |
| BSLN.SW Basilea Pharmaceutica AG | $940M | 15.5 | 130.7 | 170.3 | 23.5 | 33.6 | 8 | BULLISH | 41.8 |
| ACIU AC Immune S.A. | $280M | -5.3 | -78.5 | 96.7 | 12.4 | -39.5 | 2 | NEUTRAL | -13.4 |
| BANB.SW Bachem Holding AG | $6.8B | 39.8 | 20.6 | 17.3 | 15.4 | 24.4 | 6 | NEUTRAL | 22.1 |
| PHVS Pharvaris N.V. | $2.2B | -10.1 | -70.7 | 860.9 | — | — | 4 | BEARISH | 31.5 |
| IDIA.SW Idorsia Ltd | $1.4B | -3.4 | 27.1 | -526.5 | -201.9 | -8.0 | 1 | BEARISH | 68.0 |
| MLTX MoonLake Immunotherapeutics | $960M | -3.0 | -67.4 | 2902.7 | — | — | 1 | BEARISH | 52.5 |
| 0RQE.IL Idorsia Ltd. | $1.2B | — | — | — | — | — | — | BEARISH | — |
| OCS Oculis Holding AG | $500M | -5.3 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -51.0 |
| VECT VectivBio Holding AG | $1.1B | -8.0 | -84.7 | -5479.4 | -4212.8 | — | 2 | N/A | 182.7 |
| 6160.HK BeOne Medicines AG | $282B | 61.2 | 14.6 | 57.1 | 13.9 | 34.2 | 8 | BULLISH | 12.8 |
| LONN.SW Lonza Group AG | $49B | -373.2 | 7.1 | 17.8 | 17.5 | 3.1 | 6 | BULLISH | -0.6 |
| CRSP CRISPR Therapeutics AG | $5.3B | -12.0 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BULLISH | -21.3 |
| 688235.SS BeOne Medicines Ltd. Class A | $276B | 26.3 | 14.7 | 57.4 | 13.9 | 31.9 | 8 | BULLISH | 17.7 |
| BSLN.SW Basilea Pharmaceutica AG | $940M | 15.5 | 130.7 | 170.3 | 23.5 | 33.6 | 8 | BULLISH | 41.8 |
| ACIU AC Immune S.A. | $280M | -5.3 | -78.5 | 96.7 | 12.4 | -39.5 | 2 | NEUTRAL | -13.4 |
| BANB.SW Bachem Holding AG | $6.8B | 39.8 | 20.6 | 17.3 | 15.4 | 24.4 | 6 | NEUTRAL | 22.1 |
| PHVS Pharvaris N.V. | $2.2B | -10.1 | -70.7 | 860.9 | — | — | 4 | BEARISH | 31.5 |
| IDIA.SW Idorsia Ltd | $1.4B | -3.4 | 27.1 | -526.5 | -201.9 | -8.0 | 1 | BEARISH | 68.0 |
| MLTX MoonLake Immunotherapeutics | $960M | -3.0 | -67.4 | 2902.7 | — | — | 1 | BEARISH | 52.5 |
| 0RQE.IL Idorsia Ltd. | $1.2B | — | — | — | — | — | — | BEARISH | — |
| OCS Oculis Holding AG | $500M | -5.3 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -51.0 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
VECT vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
P/E Ratio
ROE
Piotroski F